| ₹ crore | Q1 FY27 | Q1 FY26 | Change |
|---|---|---|---|
| Revenue | 377 | 137 | +174.8% |
| EBITDA | 59.1 | 25.2 | +134.7% |
| EBITDA margin | 15.7% | 18.4% | −2.7 pts |
| Profit before tax | 64.7 | 31.5 | +105.6% |
| Net profit | 48.2 | 25.0 | +92.6% |
| EPS | ₹0.41 | ₹2.18 | −81.2% |
Amounts on the left scale in ₹ crore; per cent on the right, dashed. L = lakh crore, K = thousand crore. Touch the chart to read any period.
| Tap a line for its trend | Currentlast 12M | FY26Mar 2026 | FY25Mar 2025 | FY24Mar 2024 | FY23Mar 2023 | FY22 and earlierAlpha Plus |
|---|
| 5,824 | — | — | — | — | FY22 and earlierEvery year the company has filed comes with Alpha Plus. | |
| 64.3 | 64.3 | 29.3 | 61.5 | 37.6 | ||
| 57.3 | 57.3 | 7.6 | 6.5 | 7.0 | ||
| 8.2 | 8.2 | 0.2 | 5.2 | 7.3 | ||
| 5,825 | — | — | — | — | ||
| 1,012 | 772 | 533 | 569 | 517 | ||
| — | +44.8% | −6.3% | +10.1% | — | ||
| 169 | 135 | 127 | 148 | 113 | ||
| 16.7% | 17.5% | 23.9% | 26.1% | 21.8% | ||
| 154 | 121 | 118 | 142 | 108 | ||
| 148 | 125 | 109 | 121 | 89.6 | ||
| 14.6% | 16.2% | 20.5% | 21.3% | 17.3% | ||
| ₹1.05 | ₹0.93 | ₹0.93 | ₹1.03 | ₹0.76 | ||
| — | +0.5% | −9.7% | +35.7% | — | ||
| — | −23.8 | 69.3 | 97.4 | 108 | ||
| — | −24.6 | −67.9 | −47.9 | −19.5 | ||
| −48.4 | −48.4 | 1.4 | 49.5 | 88.7 | ||
From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.
In ₹ Crore except Per Share 12 Months Ending | FY23 31/03/2023 | FY24 31/03/2024 | FY25 31/03/2025 | FY26 31/03/2026 | Current/LTM TTM · last close | |
|---|---|---|---|---|---|---|
| Market Capitalization | — | — | — | — | 5,823.7 | |
| - Cash, Equiv & ST Investments | 37.6 | 61.5 | 29.3 | 64.3 | 64.3 | |
| + Minority Interest | 7.0 | 6.5 | 7.6 | 57.3 | 57.3 | |
| + Total Debt | 7.3 | 5.2 | 0.2 | 8.2 | 8.2 | |
| Enterprise Value | — | — | — | — | 5,824.8 | |
| Revenue | 517.0 | 569.0 | 533.3 | 772.2 | 1,011.8 | |
| Growth %, YoY | — | +10.1 | -6.3 | +44.8 | — | |
| EBITDA | 112.6 | 148.4 | 127.2 | 134.7 | 168.7 | |
| Margin % | 21.78 | 26.08 | 23.85 | 17.45 | 16.67 | |
| EBIT | 108.3 | 142.4 | 118.0 | 121.3 | 153.6 | |
| Net Income | 89.6 | 121.0 | 109.2 | 125.0 | 148.2 | |
| Margin % | 17.32 | 21.27 | 20.48 | 16.19 | 14.65 | |
| EPS, Adj (current shares) | 0.76 | 1.03 | 0.93 | 0.93 | 1.05 | |
| Growth %, YoY | — | +35.7 | -9.7 | +0.5 | — | |
| Cash from Operations | 108.2 | 97.4 | 69.3 | -23.8 | — | |
| Capital Expenditures | -19.5 | -47.9 | -67.9 | -24.6 | — | |
| Free Cash Flow | 88.7 | 49.5 | 1.4 | -48.4 | -48.4 | |
Prices at the 29 October 2026 close · figures from the company's filings with NSE
Fineotex Chemical (NSE: FCL) had a market capitalisation of ₹5,961 crore at the 29 October 2026 close (₹51.19 a share), a PE ratio of 48.7 on the last four quarters' profit and a price-to-book ratio of 6.76. In FY26 its consolidated net profit attributable to shareholders was ₹109 crore on revenue of ₹772 crore; in Q1 FY27 (April–June 2026) it was ₹38.4 crore, up 54.8% year on year. Its debt-to-equity ratio was 0.01 on 31 March 2026. Promoters held 62.30% of the shares on 30 September 2026.
Fineotex Chemical's PE ratio is 48.7 at the 29 October 2026 close (₹51.19 a share): a market capitalisation of ₹5,961 crore divided by consolidated net profit attributable to shareholders of ₹122 crore over the last four quarters (Q2 FY26 to Q1 FY27). On FY26 net profit attributable to shareholders (₹109 crore) it is 54.8.
Fineotex Chemical's price-to-book (PB) ratio is 6.76 at the 29 October 2026 close: a market capitalisation of ₹5,961 crore divided by shareholders' equity (book value) of ₹882 crore on 31 March 2026. That is a book value of ₹7.58 per share against a share price of ₹51.19.
Fineotex Chemical's debt-to-equity ratio was 0.01 on 31 March 2026: borrowings of ₹8.2 crore against total equity of ₹940 crore. A year earlier, on 31 March 2025, it was 0.00.
Fineotex Chemical's market capitalisation was ₹5,961 crore at the 29 October 2026 close: 116.45 crore shares at ₹51.19 each.
No. Fineotex Chemical had borrowings of ₹8.2 crore on 31 March 2026 (consolidated balance sheet), a debt-to-equity ratio of 0.01. Its cash and current investments were ₹73.2 crore, so it held net cash of ₹65 crore.
In 2026, Fineotex Chemical has declared one dividend: ₹0.05 with record date 4 September 2026.
Fineotex Chemical's net worth — shareholders' equity in its consolidated balance sheet — was ₹882 crore on 31 March 2026, up 20.7% from ₹731 crore a year earlier. Its market value is a different figure: a market capitalisation of ₹5,961 crore at the 29 October 2026 close.
Fineotex Chemical's book value per share was ₹7.58 on 31 March 2026: shareholders' equity of ₹882 crore divided by the 116.45 crore shares in issue. The share price at the 29 October 2026 close was ₹51.19.
Promoters held 62.30% of Fineotex Chemical on 30 September 2026, unchanged from the previous quarter and down 0.58 percentage points from 62.88% a year earlier, according to the shareholding pattern filed with NSE.
In FY26, Fineotex Chemical's return on equity (ROE) was 13.5% and its return on capital employed (ROCE) was 14.3%. ROE is net profit attributable to shareholders divided by average shareholders' equity (the start and end of the year); ROCE is operating profit (EBIT) divided by average capital employed (total assets less current liabilities). In FY25, ROE was 18.4% and ROCE 19.6%.
On 30 September 2026, Fineotex Chemical's shares were held by promoters 62.30%, foreign portfolio investors (FII/FPI) 2.01%, domestic institutions (DII) 1.64% (including mutual funds at 1.46%) and retail and other non-institutional investors 34.05%. Over the year, FII holding was down 0.33 percentage points from 2.34% and DII holding was up 0.01 percentage points from 1.63%.
Fineotex Chemical's latest results are for Q1 FY27 (April–June 2026), filed on 23 July 2026: consolidated net profit attributable to shareholders ₹38.4 crore, up 54.8% from ₹24.8 crore in Q1 FY26; revenue from operations ₹377 crore, up 174.8% year on year.
Fineotex Chemical's basic earnings per share (EPS) were ₹1.09 in FY26.
In FY26, Fineotex Chemical generated ₹23.8 crore of cash from operations and spent ₹24.6 crore on capital expenditure (property, plant, equipment and intangibles), leaving free cash flow of −₹48.4 crore. In FY25 it was ₹1.4 crore.
Fineotex Chemical has not yet announced the date of its Q2 FY27 results (July–September 2026); under SEBI's listing rules (Regulation 33) they are due by 14 November 2026.
In FY26 (April 2025–March 2026), Fineotex Chemical's consolidated net profit attributable to shareholders was ₹109 crore, up 0.5% from ₹108 crore in FY25, on revenue from operations of ₹772 crore (up 44.8%). Over three years, from FY23, net profit was up 23.1%.
On FY26 consolidated figures, against Epigral, Yasho Industries and Gujarat Alkalies and Chemicals: Fineotex Chemical's operating margin of 15.7% is the second highest of the four (Epigral 15.8%, Yasho Industries 10.7%, Gujarat Alkalies and Chemicals −0.2%; peer average 8.7%); its return on equity of 13.5% is the second highest of the four (Epigral 16.1%, Yasho Industries 5.9%, Gujarat Alkalies and Chemicals −0.0%; peer average 7.3%).
In FY26, Fineotex Chemical earned net profit attributable to shareholders of ₹109 crore on revenue of ₹772 crore, against ₹332 crore on ₹2,527 crore for Epigral. Fineotex Chemical's operating margin was 15.7% (Epigral 15.8%) and its return on equity 13.5% (Epigral 16.1%). At the 29 October 2026 close, Fineotex Chemical's market capitalisation was ₹5,961 crore against ₹3,914 crore for Epigral, and its PE ratio on FY26 profit 54.8 against 11.8.
From Fineotex Chemical's own consolidated results, balance sheets and shareholding patterns filed with NSE, and NSE prices (the latest used here: the 29 October 2026 close). Ratios are calculated by Alphave from those filings as each answer describes.
Consolidated figures from the company's filings with NSE; prices are NSE closing prices.